Life After Chevron: US Supreme Court Ruling Cited In FDA Exclusivity Decision Challenges

Disputes over orphan and new clinical investigation exclusivity are among the early drug and biologic cases where legal filings cite the Loper Bright decision, which overturned the Chevron doctrine of deference to agency actions.

Small wave
A wave of drug and biologic lawsuits citing the Loper Bright decision is building. • Source: Shutterstock

More from Legal & IP

More from Pink Sheet